Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics, Inc. (VKTX) Q1 2023 - Earnings Call Transcript
08:55pm, Wednesday, 26'th Apr 2023
Viking Therapeutics, Inc. (VKTX) Q1 2023 - Earnings Call Transcript.
3 Top Biotech Stocks Defying the Bear Market
08:45am, Tuesday, 25'th Apr 2023
TG Therapeutics' MS drug Briumvi has had strong early sales. Viking Therapeutics reports solid clinical results from its obesity drug VK2735.
Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs
07:01am, Monday, 17'th Apr 2023
The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatment VK2735 caused its shares to rally more
Viking Therapeutics: A Promising NASH Diversification Play
07:56am, Tuesday, 04'th Apr 2023
Following positive data for its obesity drug (VK2735), Viking Therapeutics shares rallied aggressively. In Q2, Viking is poised to release its Phase 2b (VOYAGE) trial data of VK2809 for non-alcoholic
5 Best Stocks to Buy in April
01:43pm, Saturday, 01'st Apr 2023
Several key themes are emerging in the stock investing landscape. These five stocks are poised to benefit from these powerful trends.
Why Shares of Viking Therapeutics Skyrocketed This Week
02:06pm, Thursday, 30'th Mar 2023
Viking Therapeutics is seeing promise in an obesity drug. The company said it plans another phase 1 trial, as well as a phase 2 trial of VK2735.
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
11:40pm, Wednesday, 29'th Mar 2023
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient po
Viking (VKTX) Announces Clinical Data for Metabolic Disorders
12:14pm, Wednesday, 29'th Mar 2023
Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
07:45am, Wednesday, 29'th Mar 2023
Viking Therapeutics stock has already gained an astounding 463% in the past six months. With key data readouts in obesity and NASH on tap later this year, the small-cap biotech could represent a once-
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?
05:54am, Wednesday, 29'th Mar 2023
Viking Therapeutics announced promising results on Tuesday from a phase 1 study of obesity drug VX2735. If VK2735 goes on to win approval, it should have a huge market opportunity.
Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
01:01pm, Tuesday, 28'th Mar 2023
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the treatment
Viking Therapeutics Steps Into The Obesity Ring — And Catapults 63%
12:32pm, Tuesday, 28'th Mar 2023
Viking said Tuesday recipients of its potential obesity treatment lost up to 18 pounds, and VKTX stock launched to a five-year high. The post Viking Therapeutics Steps Into The Obesity Ring — And Ca
Viking Therapeutics shares up more than 50% on positive trial results for obesity drug
10:51am, Tuesday, 28'th Mar 2023
Viking Therapeutics (NASDAQ:VKTX) shares had added more than 55% on Tuesday after the biopharmaceutical company published positive early-stage data for its drug candidate targeting obesity VK2735. The
Biotech Stock Surges to 4-Year Highs on Upbeat Trial
10:12am, Tuesday, 28'th Mar 2023
Viking Therapeutics Inc (NASDAQ:VKTX) is surging, last seen up 53.7% at $14.02, after the company revealed plans to start a mid-stage trial for experimental obesity drug VK2735 later this year.
Viking's stock rallies as it announces trial for oral version of obesity drug
08:19am, Tuesday, 28'th Mar 2023
Shares of Viking Therapeutics Inc. VKTX, +3.05% soared about 45% in premarket trading on Tuesday after the company said it started a Phase 1 clinical trial evaluating an oral version of its dual gluca
